Document Detail

Drug-eluting stents: a critique.
MedLine Citation:
PMID:  18195121     Owner:  NLM     Status:  MEDLINE    
Despite advances in the design of balloons and stents, restenosis remains a major drawback of coronary angioplasty. Multiple randomised trials have demonstrated that drug-eluting stents (DES) can significantly reduce rates of restenosis by 60-75% across both lesion and patient subsets. In recent years there has been an exponential increase in the worldwide use of DES. This expansion has occurred as a result of an enthusiastic extrapolation of results from randomised trials leading to "off-label" use of DES in anatomical or clinical high-risk scenarios, or both. However, emerging medium- to long-term follow-up data have raised concerns about the safety of DES. A number of analyses have recently shown increased rates of late stent thrombosis in patients with DES. The exact mechanisms leading to stent thrombosis remain unclear. This article critically reviews the available efficacy and safety data on DES and discusses the factors influencing our current practice and perception of the net value of DES.
N Melikian; W Wijns
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Heart (British Cardiac Society)     Volume:  94     ISSN:  1468-201X     ISO Abbreviation:  Heart     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-01-15     Completed Date:  2008-01-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9602087     Medline TA:  Heart     Country:  England    
Other Details:
Languages:  eng     Pagination:  145-52     Citation Subset:  AIM; IM    
Cardiovascular Centre Aalst, OLV Ziekenhuis, Moorselbaan 164, 9300 Aalst, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary / methods,  mortality
Blood Vessel Prosthesis*
Coronary Restenosis / mortality,  prevention & control*
Diabetic Angiopathies / mortality,  therapy
Drug-Eluting Stents / adverse effects*
Graft Occlusion, Vascular / etiology*,  mortality
Prosthesis Failure
Randomized Controlled Trials as Topic
Risk Factors
Treatment Outcome

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Economic burden and the cost-effectiveness of treatment of cardiovascular diseases in Africa.
Next Document:  Endovascular infrarenal abdominal aortic aneurysm repair.